A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumours and Varying Degrees of Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients
with lymphoma, chronic lymphocytic leukemia, or solid tumours with liver dysfunction.
Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking
the activity of proteins that are important for the cancer's growth and survival.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society